Byetta is a brand name of exenatide, approved by the FDA in the following formulation(s):
BYETTA (exenatide synthetic - injectable; subcutaneous)
Manufacturer: AMYLIN
Approval date: April 28, 2005
Strength(s): 300MCG/1.2ML (250MCG/ML) [RLD], 600MCG/2.4ML (250MCG/ML) [RLD]
Has a generic version of Byetta been approved?
No. There is currently no therapeutically equivalent version of Byetta available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Byetta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
Patent 5,424,286
Issued: June 13, 1995
Inventor(s): Eng; John
This invention encompasses pharmaceutical compositions containing exendin-3 or exendin-4, fragments thereof, or any combination thereof, and methods for the treatment of diabetes mellitus and the prevention of hyperglycemia.Patent expiration dates:
- December 1, 2016✓
- December 1, 2016✓
- December 1, 2016
Methods for regulating gastrointestinal motility
Patent 6,858,576
Issued: February 22, 2005
Inventor(s): Young; Andrew A. & Gedulin; Bronislava & Beeley; Nigel Robert Arnold & Prickett; Kathryn S.
Assignee(s): Amylin Pharmaceuticals, Inc.
Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.Patent expiration dates:
- January 6, 2017✓
- January 6, 2017
Methods for glucagon suppression
Patent 6,872,700
Issued: March 29, 2005
Inventor(s): Young; Andrew A. & Gedulin; Bronislava
Assignee(s): Amylin Pharmaceuticals, Inc.
Methods for use of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, for lowering glucagon levels and/or suppressing glucagon secretion in a subject are provide. These methods are useful in treating hyperglucagonemia and other conditions that would be benefited by lowering plasma glucagon or suppressing glucagon secretion.Patent expiration dates:
- January 14, 2020✓
- January 14, 2020
Exendin agonist formulations and methods of administration thereof
Patent 6,902,744
Issued: June 7, 2005
Inventor(s): Kolterman; Orville G. & Young; Andrew A.
Assignee(s): Amylin Pharmaceuticals, Inc.
Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.Patent expiration dates:
- January 14, 2020✓
- January 14, 2020
Use of exendins for the reduction of food intake
Patent 6,956,026
Issued: October 18, 2005
Inventor(s): Beeley; Nigel Robert Arnold & Bhavsar; Sunil
Assignee(s): Amylin Pharmaceuticals, Inc.
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Patent expiration dates:
- January 7, 2018✓
- January 7, 2018
Pharmaceutical compositions containing exendins
Patent 7,297,761
Issued: November 20, 2007
Inventor(s): Beeley; Nigel Robert Arnold & Prickett; Kathryn S. & Bhavsar; Sunil & Young; Andrew & Gedulin; Bronislava
Assignee(s): Amylin Pharmaceuticals, Inc.
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Patent expiration dates:
- October 15, 2017✓
- October 15, 2017
Exendin pharmaceutical compositions
Patent 7,521,423
Issued: April 21, 2009
Inventor(s): Young; Andrew A. & Gedulin; Bronislava
Assignee(s): Amylin Pharmaceuticals, Inc.
Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.Patent expiration dates:
- October 15, 2017✓
- October 15, 2017
Exendins and exendin agonists for weight reduction and obesity
Patent 7,741,269
Issued: June 22, 2010
Inventor(s): Young; Andrew A. & Bhavsar; Sunil & Gedulin; Bronislava
Assignee(s): Amylin Pharmaceuticals, Inc.
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.Patent expiration dates:
- January 7, 2018✓
- January 7, 2018
See also...
- Byetta Consumer Information (Drugs.com)
- Byetta Consumer Information (Wolters Kluwer)
- Byetta Consumer Information (Cerner Multum)
- Byetta Prefilled Pen Consumer Information (Cerner Multum)
- Byetta Advanced Consumer Information (Micromedex)
- Byetta AHFS DI Monographs (ASHP)
- Exenatide Consumer Information (Wolters Kluwer)
- Exenatide Consumer Information (Cerner Multum)
- Exenatide Subcutaneous Advanced Consumer Information (Micromedex)
- Exenatide AHFS DI Monographs (ASHP)
No comments:
Post a Comment